Rapamycin in combination with donor-specific CD4+CD25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation

Zhang, Chuntao; Shan, Juan; Lu, Jun; Yongsheng, Huang; Li, Feng; Long, Dan; Li, Shengfu; Li, Quansheng; Li, Youping

doi:10.1016/j.cellimm.2010.05.014

Cited by 11 publications

(12 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These expanded Treg cells suppress proliferation of T cells in vitro and prevent allograft rejection in vivo [18]. Subsequently, a large number of research reported that rapamycin spared and promoted growth of functional Treg cells in the field of transplantation immunology and autoimmune diseases [19–24]. Until now, due to the safety and efficacy of rapamycin in clinical trials, it is under more intensive investigation for the treatment of various immune-mediated disorders, including type 1 diabetic, systemic lupus erythematosus and rheumatoid arthritis [25, 26].…”

Section: Introductionmentioning

confidence: 99%

Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune Thrombocytopenia

Wang

Dai

et al. 2013

Clinical and Developmental Immunology

View full text Add to dashboard Cite

We conducted this randomized trial to investigate the efficacy and safety of rapamycin treatment in adults with chronic immune thrombocytopenia (ITP). Eighty-eight patients were separated into the control (cyclosporine A plus prednisone) and experimental (rapamycin plus prednisone) groups. The CD4+CD25+CD127low regulatory T (Treg) cells level, Foxp3 mRNA expression, and the relevant cytokines levels were measured before and after treatment. The overall response (OR) was similar in both groups (experimental group versus control group: 58% versus 62%, P = 0.70). However, sustained response (SR) was more pronounced in the experimental group than in the control group (68% versus 39%, P < 0.05). Both groups showed similar incidence of adverse events (7% versus 11%, P = 0.51). As expected, the low pretreatment baseline level of Treg cells was seen in all patients (P < 0.001); however, the experimental group experienced a significant rise in Treg cell level, and there was a strong correlation between the levels of Treg cells and TGF-beta after the treatment. In addition, the upregulation maintained a stable level during the follow-up phase. Thus, rapamycin plus low dose prednisone could provide a new promising option for therapy of ITP.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune Thrombocytopenia

Wang

Dai

et al. 2013

Clinical and Developmental Immunology

View full text Add to dashboard Cite

show abstract

“…It has also been postulated from animal models of transplantation that a combination of rapamycin and Tregs may be successful in inducing and maintaining tolerance. 32,33 Fully effective structural and conditional tolerance might preclude the mounting of a protective immune response against common pathogens. Therefore, it may be postulated that future strategies should consider an orchestrated combination of accommodation and tolerance because a certain amount of residual immunity against self or graft would be needed for protection when battling invasive organisms.…”

Section: Methods To Sustain Accommodationmentioning

confidence: 99%

Current and future challenges in therapy for antibody-mediated rejection

Nair

Ball

Uber

et al. 2011

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Rapamycin (also known as sirolimus), a macrolide antibiotic that inhibits cell cycle progression in T cells, might induce conversion of peripheral CD4 + CD25 − T cells to CD4 + FOXP3 + Tregs potentially able to suppress effector T cell proliferation while maintaining their antigenic specificity (119). Sirolimus favorably regulates the Th17/Treg axis; this was demonstrated by suppression of Th17 and upregulation of Treg, which contribute to kidney graft acceptance (120).…”

Section: Regulatory T Cellmentioning

confidence: 99%

Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis

et al. 2017

View full text Add to dashboard Cite

The transcription factor forkhead box protein 3 (FOXP3) is an essential molecular marker of regulatory T cell (Treg) development in different microenvironments. Tregs are cells specialized in the suppression of inadequate immune responses and the maintenance of homeostatic tolerance. Studies have addressed and elucidated the role played by FOXP3 and Treg in countless autoimmune and infectious diseases as well as in more specific cases, such as cancer. Within this context, the present article reviews aspects of the immunoregulatory profile of FOXP3 and Treg in the management of immune homeostasis, including issues relating to pathology as well as immune tolerance.

show abstract

Rapamycin in combination with donor-specific CD4+CD25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation

Cited by 11 publications

References 50 publications

Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune Thrombocytopenia

Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune Thrombocytopenia

Current and future challenges in therapy for antibody-mediated rejection

Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis

Contact Info

Product

Resources

About